US-based Loxo Oncology has announced that its lead clinical program is a potent and selective inhibitor of the Trk family of receptor tyrosine kinases. Loxo Oncology acquired rights to this program from Array Biopharma, which had pursued ...
Tags: Loxo Oncology, Medicine